Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer

Clinical, pathological, and PAM50 gene expression features of HER2-low breast cancer

Abstract Novel antibody-drug conjugates against HER2 are showing high activity in HER2-negative breast cancer (BC) with low HER2 expression (i.e., 1+ or 2+ and lack of ERBB2 amplification). However, the clinical and molecular features of HER2-low BC are yet to be elucidated. Here, we collected retro...

Full description

Bibliographic Details
Main Authors: Francesco Schettini, Nuria Chic, Fara Brasó-Maristany, Laia Paré, Tomás Pascual, Benedetta Conte, Olga Martínez-Sáez, Barbara Adamo, Maria Vidal, Esther Barnadas, Aranzazu Fernández-Martinez, Blanca González-Farre, Esther Sanfeliu, Juan Miguel Cejalvo, Giuseppe Perrone, Giovanna Sabarese, Francesca Zalfa, Vicente Peg, Roberta Fasani, Patricia Villagrasa, Joaquín Gavilá, Carlos H. Barrios, Ana Lluch, Miguel Martín, Mariavittoria Locci, Sabino De Placido, Aleix Prat
Format: Article
Language:English
Published: Nature Publishing Group 2021-01-01
Series:npj Breast Cancer
Online Access:https://doi.org/10.1038/s41523-020-00208-2

Internet

https://doi.org/10.1038/s41523-020-00208-2

Similar Items